Company Profile

21st Century Therapeutics Inc
Profile last edited on: 10/31/22      CAGE: 47RG2      UEI: YR4CUFNLGKL8

Business Identifier: New drugs: cancer and immune-mediated diseases
Year Founded
2002
First Award
2005
Latest Award
2018
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

440 Burroughs Street Suite 447
Detroit, MI 48202
   (248) 545-0595
   info@21-cti.com
   www.21-cti.com
Location: Single
Congr. District: 13
County: Wayne

Public Profile

21st Century Therapeutics is a product-focused, development-oriented biotech company that very soon after being founded placed six anti-tumor compounds into human clinical studies through licensing to pharmaceutical companies. The firm's exclusive ORION discovery and development platform combines a unique and novel in vitro Solid Tumor Selective (STS) technology with an exclusive Chemistry, Clonogenic, Formulation and Pharmacology studies (CCFP) platform to ensure that its drugs will be bioavailable and active in subsequent in vivo Therapeutic Assessment. Data from all these components, together with a Molecular Brushing (MB) platform, are blended in a proprietary manner to identify and characterize potential clinical strengths and weaknesses of an experimental anti-cancer drug. The added value of this approach includes early stage prediction of the drug’s therapeutic effectiveness in humans as well as the novel target mechanism by which it acts

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Key People / Management

  Jiajiu Shaw -- President

  Jiajiu "jj" Shaw -- President

  Frederick Valeriote -- CEO

  Russell Lloyd Betts

  Ben D Chen -- Associate Professor

  Alexander Nakeff